Search results
Results from the WOW.Com Content Network
C-reactive protein (CRP) is an annular (ring-shaped) pentameric protein found in blood plasma, whose circulating concentrations rise in response to inflammation.It is an acute-phase protein of hepatic origin that increases following interleukin-6 secretion by macrophages and T cells.
The disorder is sometimes called chronic relapsing polyneuropathy (CRP) or chronic inflammatory demyelinating polyradiculoneuropathy (because it involves the nerve roots). [2] CIDP is closely related to Guillain–Barré syndrome and it is considered the chronic counterpart of that acute disease. [ 3 ]
Another test that checks the level of C-reactive protein (CRP) in the blood may also be conducted. CRP is produced by the liver in response to an injury or infection, and people with polymyalgia rheumatica usually have high levels. [17] [18] However, like the ESR, this test is also not very specific. [citation needed]
CRP may refer to: Science and technology. C-reactive protein, an acute phase protein produced by the liver; cAMP receptor protein (catabolite gene activator protein)
Catabolite activator protein (CAP; also known as cAMP receptor protein, CRP) is a trans-acting transcriptional activator that exists as a homodimer in solution. Each subunit of CAP is composed of a ligand -binding domain at the N-terminus (CAP N , residues 1–138) and a DNA-binding domain at the C-terminus (DBD, residues 139–209).
Elevated levels are also associated with diabetes, hypertension, and cardiovascular disease; it was found that elevated levels are associated with elevated serum C-reactive protein (CRP), which could reflect an inflammatory and atherogenic milieu, possibly an alternative cause for elevated serum alkaline phosphatase. [10] Chronic kidney disease ...
Cysteine-rich proteins (CRP, cysteine-rich peptide or disulphide-rich peptide) are small proteins that contain a large number of cysteines. These cysteines either cross-link to form disulphide bonds , or bind metal ions by chelation , stabilising the protein's tertiary structure .
These studies demonstrated that TNF-blocker therapy improves clinical symptoms, CRP levels, and MRI-detectable inflammation in the spine or sacroiliac joints. [8] These improvements were noted with certolizumab pegol , [ 41 ] etanercept , [ 42 ] [ 43 ] infliximab , [ 44 ] [ 45 ] adalimumab , [ 46 ] and golimumab .